Literature DB >> 19342669

Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis.

Constantine Bitsaktsis1, Deepak B Rawool, Ying Li, Nitin V Kurkure, Bibiana Iglesias, Edmund J Gosselin.   

Abstract

Francisella tularensis is a category A biothreat agent for which there is no approved vaccine and the correlates of protection are not well understood. In particular, the relationship between the humoral and cellular immune response to F. tularensis and the relative importance of each in protection is controversial. Yet, understanding this relationship will be crucial to the development of an effective vaccine against this organism. We demonstrate, for the first time, a differential requirement for humoral vs cellular immunity in vaccine-induced protection against F. tularensis infection, and that the requirement for Ab observed in some protection studies, may be overcome through the induction of enhanced cellular immunity. Specifically, following intranasal/mucosal immunization of mice with inactivated F. tularensis organisms plus the cholera toxin B subunit, we observe increased production of IgG2a/2c vs IgG1 Ab, as well as IFN-gamma, indicating induction of a Th1 response. In addition, the requirement for F. tularensis-specific IgA Ab production, observed in studies following immunization with inactivated F. tularensis alone, is eliminated. Thus, these data indicate that enhanced Th1 responses can supersede the requirement for anti-F. tularensis-specific IgA. This observation also has important ramifications for vaccine development against this organism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19342669      PMCID: PMC2720832          DOI: 10.4049/jimmunol.0803242

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  70 in total

Review 1.  Improving vaccine performance with adjuvants.

Authors:  F R Vogel
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

2.  Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4.

Authors:  M Marinaro; H F Staats; T Hiroi; R J Jackson; M Coste; P N Boyaka; N Okahashi; M Yamamoto; H Kiyono; H Bluethmann; K Fujihashi; J R McGhee
Journal:  J Immunol       Date:  1995-11-15       Impact factor: 5.422

3.  Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant.

Authors:  R J Jackson; K Fujihashi; J Xu-Amano; H Kiyono; C O Elson; J R McGhee
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

4.  Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease.

Authors:  Michael Green; Glyn Choules; Debbie Rogers; Richard W Titball
Journal:  Vaccine       Date:  2005-04-08       Impact factor: 3.641

5.  Diversity of Francisella tularensis antigens recognized by human T lymphocytes.

Authors:  H M Surcel
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

6.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Authors:  Chandra Shekhar Bakshi; Meenakshi Malik; Manish Mahawar; Girish S Kirimanjeswara; Karsten R O Hazlett; Lance E Palmer; Martha B Furie; Rajendra Singh; J Andres Melendez; Timothy J Sellati; Dennis W Metzger
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

7.  Cell-mediated and humoral immune responses induced by scarification vaccination of human volunteers with a new lot of the live vaccine strain of Francisella tularensis.

Authors:  D M Waag; A Galloway; G Sandstrom; C R Bolt; M J England; G O Nelson; J C Williams
Journal:  J Clin Microbiol       Date:  1992-09       Impact factor: 5.948

8.  Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia.

Authors:  M Fulop; R Manchee; R Titball
Journal:  Vaccine       Date:  1995-09       Impact factor: 3.641

9.  Neutralization of gamma interferon and tumor necrosis factor alpha blocks in vivo synthesis of nitrogen oxides from L-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice.

Authors:  S J Green; C A Nacy; R D Schreiber; D L Granger; R M Crawford; M S Meltzer; A H Fortier
Journal:  Infect Immun       Date:  1993-02       Impact factor: 3.441

10.  Specific antibodies contribute to the host protection against strains of Francisella tularensis subspecies holarctica.

Authors:  Stephan Stenmark; Helena Lindgren; Arne Tärnvik; Anders Sjöstedt
Journal:  Microb Pathog       Date:  2003-08       Impact factor: 3.738

View more
  21 in total

1.  Defective anti-polysaccharide IgG vaccine responses in IgA deficient mice.

Authors:  Yoichi Furuya; Girish S Kirimanjeswara; Sean Roberts; Rachael Racine; Jennifer Wilson-Welder; Alan M Sanfilippo; Sharon L Salmon; Dennis W Metzger
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

2.  Antibodies contribute to effective vaccination against respiratory infection by type A Francisella tularensis strains.

Authors:  Gopi Mara-Koosham; Julie A Hutt; C Rick Lyons; Terry H Wu
Journal:  Infect Immun       Date:  2011-01-31       Impact factor: 3.441

3.  Fc receptor-targeting of immunogen as a strategy for enhanced antigen loading, vaccination, and protection using intranasally administered antigen-pulsed dendritic cells.

Authors:  Giang H Pham; Bibiana V Iglesias; Edmund J Gosselin
Journal:  Vaccine       Date:  2014-07-26       Impact factor: 3.641

4.  Ex vivo antigen-pulsed PBMCs generate potent and long lasting immunity to infection when administered as a vaccine.

Authors:  Sudeep Kumar; Raju Sunagar; Giang Pham; Edmund J Gosselin; David Nalin
Journal:  Vaccine       Date:  2017-01-06       Impact factor: 3.641

5.  Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain.

Authors:  Douglas S Reed; Le'kneitah P Smith; Kelly Stefano Cole; Araceli E Santiago; Barbara J Mann; Eileen M Barry
Journal:  Infect Immun       Date:  2014-03-10       Impact factor: 3.441

Review 6.  Technical transformation of biodefense vaccines.

Authors:  Shan Lu; Shixia Wang
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

7.  Bronchus-associated lymphoid tissue (BALT) and survival in a vaccine mouse model of tularemia.

Authors:  Damiana Chiavolini; Javier Rangel-Moreno; Gretchen Berg; Kate Christian; Laura Oliveira-Nascimento; Susan Weir; Joseph Alroy; Troy D Randall; Lee M Wetzler
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

8.  Vaccination evokes gender-dependent protection against tularemia infection in C57BL/6Tac mice.

Authors:  Raju Sunagar; Sudeep Kumar; Brian J Franz; Edmund J Gosselin
Journal:  Vaccine       Date:  2016-05-13       Impact factor: 3.641

9.  Cholera toxin B induced activation of murine macrophages exposed to a fixed bacterial immunogen.

Authors:  Kari Wiedinger; Heather Romlein; Constantine Bitsaktsis
Journal:  Ther Adv Vaccines       Date:  2015-09

10.  Utilization of cholera toxin B as a mucosal adjuvant elicits antibody-mediated protection against S. pneumoniae infection in mice.

Authors:  Kari Wiedinger; Daniel Pinho; Constantine Bitsaktsis
Journal:  Ther Adv Vaccines       Date:  2017-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.